Article description

Summary:

• The meta-analysis aim was to investigate the effect of methylene blue (MB) on vasodilatory hypotension in critically ill and perioperative patients;
• Meta-analysis of randomized controlled trials (RCT);
• The study included 11 randomized controlled trials with a study population sample size of 556 patients;
• Primary outcomes showed significantly lower mortality in the MB group (15%) compared to the control group (25%) (RR: 0.60, 95% CI, 0.43-0.84, p = 0.003, I2 = 0%), with findings confirmed in septic shock and cardiac surgery subgroups;
• Secondary outcomes showed a significantly higher mean arterial pressure(MAP) (MD, 8.4 mmHg [95% CI 5.01-11.75] p < 0.001) and systemic vascular resistance (MD, 94.5 dyn/s/cm5 [95% CI 17.73-171.15] p = 0.02) in MB group than in the control group, with no difference in cardiac output (standardized MD, 0.16 [95% CI, -0.25 to 0.57] p = 0.45) between groups;
• No differences in acute kidney injury, cerebrovascular events, de-novo start of renal replacement therapy, and myocardial injury were detected;

Conclusions:

• Methylene blue may improve survival in critically ill and perioperative patients, with reductions in ICU and hospital lengths of stay;
• Further Large-scale, pragmatic RCT studies are needed to confirm the authors’ findings.

#Methyleneblue reverses #vasodilation in #critically ill and #perioperative patients and might improve #survival

Read the article, share your comments, and participate in the EACTAIC POLLs.

Your opinion does count.